FSD Pharma Inc. | WebDisclosure

Basculer en Français

10809	Companies
234019	Keywords
162721	Articles
124999	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 03/27/2024 at 13:00, 2 years 4 months ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics

FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF

published on 03/11/2024 at 13:05, 2 years 4 months ago

FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM)

FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF

published on 03/11/2024 at 13:05, 2 years 4 months ago

FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE

published on 03/11/2024 at 13:00, 2 years 4 months ago

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment

FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF

published on 03/05/2024 at 14:05, 2 years 5 months ago

FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024

FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF

published on 03/05/2024 at 14:05, 2 years 5 months ago

FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE

published on 03/05/2024 at 14:00, 2 years 5 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects

FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF

published on 02/28/2024 at 14:00, 2 years 5 months ago

FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs

Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF

published on 02/28/2024 at 14:00, 2 years 5 months ago

FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE

published on 02/28/2024 at 14:00, 2 years 5 months ago

FSD Pharma Announces Debt Settlement
FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders

Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation

Accesswire

Published on 08/06/2026 at 11:00, 1 hour 21 minutes ago

Blue Lagoon Files Annual Financial Statements and Provides Comment on Temporary Cease Trade Order
Published on 08/06/2026 at 08:05, 4 hours 16 minutes ago

Tocvan Drills Significant Discovery On Mezquite Trend Gran Pilar 215M Of 0.6 G/T AU, From 36.6M Downhole
Published on 08/06/2026 at 03:35, 8 hours 46 minutes ago

Tunkillia Upgrade Drilling – 39,000m Phase 2 Complete Targeting JORC Resource Classification Upgrades; PFS Underway
Published on 08/06/2026 at 01:40, 10 hours 41 minutes ago

Taranis Identifies a Hydrothermally Altered, Sulfide-Bearing Intrusive Stock Associated with Historic Gold-Silver Occurrence and Connected to Thor
Published on 08/05/2026 at 23:40, 12 hours 41 minutes ago

Galantas Gold Secures Key Permitting Approvals for Andacollo Gold Project

View all ACCESSWIRE

EQS Group

Published on 08/06/2026 at 12:05, 15 minutes ago

CULTURAL DISRUPTORS AND CULINARY ICONS UNVEILED AS THE GLOBAL JURY FOR THE S.PELLEGRINO YOUNG CHEF ACADEMY COMPETITION 2026-27
Published on 08/06/2026 at 11:50, 30 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 08/06/2026 at 11:30, 51 minutes ago

Partners Group to become majority shareholder in data center power solutions provider AVK and accelerate future growth
Published on 08/06/2026 at 11:05, 1 hour 15 minutes ago

ABB invests in LevelTen Energy to advance clean energy procurement
Published on 08/06/2026 at 11:05, 1 hour 15 minutes ago

IIFL Capital partners with Flytxt to leverage Agentic AI for sustainable AUM growth

Les Echos

Published on 08/06/2026 at 08:44, 3 hours 36 minutes ago

IDI annonce la cession du groupe Talis à son fondateur, Serge Marcillaud, accompagné de l'équipe dirigeante
Published on 08/06/2026 at 08:00, 4 hours 21 minutes ago

EURAZEO ENTRE EN DISCUSSIONS EXCLUSIVES AVEC PARTNERS GROUP EN VUE DE LA CESSION DE SA PARTICIPATION DANS AROMA-ZONE ET DE SON RÉINVESTISSEMENT À SES CÔTÉS
Published on 08/06/2026 at 08:00, 4 hours 21 minutes ago

EURAZEO ENTERS INTO EXCLUSIVE DISCUSSIONS WITH PARTNERS GROUP REGARDING THE CONTEMPLATED SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT
Published on 08/06/2026 at 07:48, 4 hours 32 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 juillet 2026
Published on 08/05/2026 at 18:00, 18 hours 21 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2026

View all LES ECHOS COMFI WIRE